Product Details
| Product Name:
Tucatinib hemiethanolate |
CAS No.:
1429755-56-5 |
| Purity:
99.76% |
Supply Ability:
10g |
| Release date:
2025/07/19 |
Product Introduction
Bioactivity
| Name | Tucatinib hemiethanolate |
| Description | Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active, and selective HER2 inhibitor with an IC50 of 8 nM. |
| In vitro | Tucatinib hemiglycolate has nanomolar activity against purified HER2 enzyme and is approximately 500-fold selective for HER2 over EGFR in cell-based assays. Tucatinib selectively inhibits the receptor tyrosine kinase HER2 but not EGFR[1]. |
| In vivo | Tucatinib hemiethanolate (ONT-380 hemiethanolate, 200 mg/kg/d) improves survival at maximum-tolerated dose[1] and reduces brain pErbB2 levels by 80%[2]. This compound (ARRY-380 hemiethanolate) shows significant tumor growth inhibition (TGI)—50% at 50 mg/kg/d and up to 96% at 100 mg/kg/d, with over 50% reduction in baseline tumor size in 9 out of 12 animals at the higher dosage. When combined with trastuzumab at 50 mg/kg/d, it achieves 98% TGI, with complete regressions in 9 out of 12 animals and partial regressions in two[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 125 mg/mL (248.23 mM), Sonication is recommended.
|
| Keywords | Tucatinib | HER2 |
| Inhibitors Related | Tucatinib | AG-1478 | (S)-Afatinib | Mollugin | Terodiline | Tannic acid | Afatinib Dimaleate | Neratinib | Cisapride | Pyrotinib dimaleate | AG1557 | VU 0240551 |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Tyrosine Kinase Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2680616-96-8
$175.00 / 1mg
-
CAS:573-20-6
$55.00 / 1mL
-
CAS:937263-43-9
$30.00 / 2mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$0.00/1kg |
VIP6Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2023-02-18 |
|
|
$0.00/10mg |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-09-20 |
|
|
$0.00/25KG |
VIP6Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2024-10-22 |
United States